- Home
- OSRH vs ADVB Comparison
OSRH vs ADVB Comparison
Compare OSRH & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSRH | ADVB |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | 21 | 31 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 10.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OSRH | ADVB |
|---|---|---|
| Price | $0.54 | $5.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.2M | 82.6K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.19 |
| 52 Week High | $1.79 | $7.70 |
Technical Indicators
Market Signals| Indicator | OSRH | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 45.45 |
| Support Level | $0.47 | $0.33 |
| Resistance Level | $0.59 | $5.95 |
| Average True Range (ATR) | 0.13 | 0.95 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 28.38 | 7.99 |
Price Performance
Historical ComparisonAbout OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About ADVB Advanced Biomed Inc.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.